BRAF and breast ductal adenocarcinoma: There were no complete responses; one patient (3%) had a confirmed partial response (a patient with breast ductal adenocarcinoma and a BRAF G469E mutation), while 10 patients had stable disease as their best response (clinical benefit rate 34%).